DIAGENICS is a biopharmaceutical company located in Woburn (Boston), MA (USA) with its European headquarters in Duesseldorf, Germany. Our unique business model strives to build a Bridge from Science to Business™. In this way we aspire to a leading position in the diagnostic field. We are currently focussing on the detection of heart infarction through a new and patented heartmarker.

DIAGENICS constantly observes scientific results and compares them with the needs of market and economy. Thus, many promising projects are targeted, licensed and quickly developed until they are ready for the market.

With DIACORDON™, DIAGENICS has already launched its first product line for the diagnosis of infarction. Besides the development of a sophisticated ACS biochip device DAGENICS plans to widen its supply with projects on stroke diagnosis.